Compare Amphastar Pharmaceuticals Inc (AMPH) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

XLRE trades at $44.45, up 0.5% with neutral technical signals and mixed moving averages. The ETF shows resilience amid interest rate volatility, with real estate ETFs outperforming broader markets despite inflation concerns. Recent news highlights XLRE's low 0.08% expense ratio advantage over competitors and steady dividend distributions, though short interest in REITs edged higher in May.

Outlook remains balanced with potential from REIT sector recovery and diversification benefits, but faces headwinds from rising Treasury yields and inflation. The 3.4% dividend yield provides income appeal, though rate sensitivity and economic uncertainty warrant cautious monitoring of fundamental improvements in property markets.